P/B
0,8
Rocket Pharmaceuticals
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
$284.9M
Market Cap • 9/25/2026
1999
(27 years)
Founded
2015
(11 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
3,3
EPS
—
Market Cap
Market Cap
284,9M
EV
25,9M
EV/Revenue
0
EV/EBITDA
-0,1
EV/EBIT
-0,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-1,4B
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
1,3%
Capex/OCF
-0,1%
SBC/OCF
—
% PPE
15,9%
% Goodwill
9,3%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
3,7%
CAGR Net Income 5Y
-86,3%
CAGR EPS 5Y
-43%
CAGR OCF 5Y
12,8%
Leverage
N.D./EBITDA
1,4
Debt/Equity
0%
Current Ratio
9,2
Quick Ratio
9,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!